SCHEMBL21404464

SCHEMBL21404464

Cn1cc(-c2nn(C)c3ncc(B4OC(C)(C)C(C)(C)O4)cc23)cn1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CREBBP Q92793 4/20 0.40
PIM1 P11309 1/20 0.35
AXL P30530 9/20 0.33
TYRO3 Q06418 2/20 0.33
FFAR1 O14842 1/20 0.33
BRD4 O60885 1/20 0.33
EP300 Q09472 1/20 0.33
CECR2 Q9BXF3 1/20 0.33
BRD9 Q9H8M2 1/20 0.33
PIK3CD O00329 2/20 0.33
GSK3A P49840 1/20 0.33
GSK3B P49841 1/20 0.33
MERTK Q12866 1/20 0.32
JAK2 O60674 1/20 0.31
JAK1 P23458 1/20 0.31
TYK2 P29597 1/20 0.31
JAK3 P52333 1/20 0.31
SIGMAR1 Q99720 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17673167 0.81 CREBBP (0.43) CREBBPBRD4EP300CECR2BRD9
SCHEMBL31496275 0.81 CREBBP (0.43) CREBBPBRD4EP300CECR2BRD9
SCHEMBL22554268 0.81 GRM5 (0.42) PIM1PIK3CDGSK3AGSK3BMERTK
SCHEMBL30895241 0.79 GSK3B (0.37) FFAR1GSK3AGSK3B
SCHEMBL14883750 0.77 SPR (0.39) FFAR1GSK3AGSK3B
SCHEMBL17673262 0.76 GSK3A (0.35) CREBBPFFAR1BRD4GSK3AGSK3B
SCHEMBL21404425 0.75 AXL (0.49) CREBBPPIM1AXLBRD4EP300
SCHEMBL31645928 0.74 FFAR1 (0.40) PIM1FFAR1PIK3CDJAK2JAK1
SCHEMBL30603626 0.74 GSK3A (0.35) FFAR1GSK3AGSK3B
SCHEMBL26135792 0.74 GSK3A (0.35) FFAR1GSK3AGSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250127792-A1 IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2025-04-24 US disclosed
US-12186324-B2 Imidazopiperazine inhibitors of transcription activating proteins BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2025-01-07 US disclosed
CN-112165944-B Imidazopiperazine inhibitors of transcriptional activator proteins 德州大学系统董事会 2024-04-09 CN disclosed
US-20230008047-A1 IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2023-01-12 US disclosed
US-20230008047-A1 IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2023-01-12 US disclosed
US-11058688-B2 Imidazopiperazine inhibitors of transcription activating proteins BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2021-07-13 US disclosed
US-11058688-B2 Imidazopiperazine inhibitors of transcription activating proteins BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2021-07-13 US disclosed
CN-112165944-A Imidazopiperazine inhibitors of transcriptional activator proteins 德州大学系统董事会 2021-01-01 CN disclosed
WO-2019191667-A1 IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2019-10-03 WO disclosed
US-20190298729-A1 IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2019-10-03 US disclosed
US-20190298729-A1 IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2019-10-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11058688-B2 Imidazopiperazine inhibitors of transcription activating proteins EP300, CREBBP, RBBP7 CREBBP 2/4885PIM1 1435/4885AXL 4678/4885
US-20230008047-A1 IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS EP300, CREBBP, RBBP7 CREBBP 2/4885PIM1 1435/4885AXL 4678/4885
US-20250127792-A1 IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS EP300, CREBBP, RBBP7 CREBBP 2/4885PIM1 1435/4885AXL 4678/4885
US-12186324-B2 Imidazopiperazine inhibitors of transcription activating proteins EP300, CREBBP, RBBP7 CREBBP 2/4885PIM1 1435/4885AXL 4678/4885
US-20190298729-A1 IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS EP300, CREBBP, RBBP7 CREBBP 2/4885PIM1 1435/4885AXL 4678/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.